ETFs & Funds
Aeterna Zentaris Shares Are Currently Undervalued And Provide Upside, Says H.C. Wainwright
This stock has been in the 1.10-1.20 range for 5 months now. Not going anywhere until word from the FDA, expected in Nov I believe...
Add a reply...
Latest StockTalks »
people get AEZS breaking news and analysis by email alert.
Get email alerts on AEZS »
AEterna Zentaris, Inc.
Get latest price
From other sites
Aeterna Zentaris to Continue Phase III Study of Cancer Drug - Analyst Blog
at Zacks.com (Apr 29, 2015)
Aeterna Zentaris Inc. (AEZS) in Focus: Stock Jumps 5.3% - Tale of the Tape
at Zacks.com (Mar 23, 2015)
Aeterna Zentaris: Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin in Prostate Cancer Published in Clinical Cancer Research
at Benzinga.com (Dec 29, 2014)
Midday movers: Kate Spade, Apple, Hospira & more
at CNBC.com (Nov 6, 2014)
Biotech's a Buy, but Hold Off on HMOs: Fund Manager
at CNBC.com (Jan 9, 2013)